Ronald G Victor MDDirector, Cedars-Sinai Center for Hypertension, Cedars-Sinai Heart Institute, Los Angeles, CA Associate Director, Clinical Research, Cedars-Sinai Heart Institute; Burns and Allen Chair in Cardiology Research, Cedars-Sinai Heart Institute
Dr. Victor completed his undergraduate work at Cornell University in Ithaca, New York, and subsequently earned a medical degree from Tulane University School of Medicine in New Orleans, Louisiana. He completed his internship and residency in internal medicine at the University of California, Los Angeles, and a cardiology fellowship at Duke University in Durham, North Carolina. He also completed a special cardiovascular research fellowship at the University of Iowa and a visiting fellowship in clinical neurophysiology at the University of Uppsala in Uppsala, Sweden.
Dr. Victor is currently Director of the Cedars-Sinai Center for Hypertension at the Cedars-Sinai Medical Center in Los Angeles, California, Associate Director of Clinical Research at Cedars-Sinai, and the Burns and Allen Chair in Cardiology Research at the Cedars-Sinai Heart Institute.
Dr. Victor has been awarded numerous grants from the National Institutes of Health and other organizations for his studies in heart disease. His research focuses on the neural mechanisms of hypertension and hypertension in special populations. He is widely published and is on the board of several industry publications, including the American Journal of Hypertension. He is also active in many organizations, including the American Society of Hypertension.
Ronald G. Victor, MD serves as a consultant for Eli Lilly, Capricor, and Ironwood Pharmaceuticals.
Ronald G. Victor, MD has received research/grant support from Eli Lilly and Capricor.
Recent Contributions to PracticeUpdate:
- Blood Pressure Lowering for Prevention of Cardiovascular Disease and Death
- 2015 Top Stories in Cardiology: Hypertension: SPRINT (Systolic Blood Pressure Intervention Trial)
- Blood Pressure Control and Risk of Stroke in Atrial Fibrillation
- Intensive vs Standard Blood Pressure Control
- Risks of β-Blocker Use in Noncardiac Surgery
- Spironolactone Versus Placebo, Bisoprolol, and Doxazosin to Determine the Optimal Treatment for Drug-Resistant Hypertension
- Landmark SPRINT Trial Stopped Early Due to Dramatic Benefits of Intensive Reduction in Systolic Blood Pressure
- Landmark NIH Study Shows Intensive Blood Pressure Management May Save Lives
- Antihypertensive Therapy Adherence and Heart Failure Risk
- Home Blood Pressure Monitoring Thresholds in Octogenarians